Online citations, reference lists, and bibliographies.
← Back to Search

Melanoma: Oncogenic Drivers And The Immune System.

N. Karachaliou, S. Pilotto, C. Teixidó, S. Viteri, M. Gonzalez-Cao, A. Riso, D. Morales-espinosa, M. Molina, I. Chaib, M. Santarpia, E. Richardet, E. Bria, R. Rosell
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Advances and in-depth understanding of the biology of melanoma over the past 30 years have contributed to a change in the consideration of melanoma as one of the most therapy-resistant malignancies. The finding that oncogenic BRAF mutations drive tumor growth in up to 50% of melanomas led to a molecular therapy revolution for unresectable and metastatic disease. Moving beyond BRAF, inactivation of immune regulatory checkpoints that limit T cell responses to melanoma has provided targets for cancer immunotherapy. In this review, we discuss the molecular biology of melanoma and we focus on the recent advances of molecularly targeted and immunotherapeutic approaches.
This paper references
10.1158/0008-5472.CAN-14-2785
PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.
M. Scortegagna (2015)
10.1016/S0198-8859(03)00122-8
Changes in the number of CD80(+), CD86(+), and CD28(+) peripheral blood lymphocytes have prognostic value in melanoma patients.
J. Martínez-Escribano (2003)
10.1158/1078-0432.CCR-08-0575
KIT Gene Mutations and Copy Number in Melanoma Subtypes
C. Beadling (2008)
10.1038/NRD773
Protein kinases — the major drug targets of the twenty-first century?
P. Cohen (2002)
10.1200/JCO.2010.32.4327
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
G. Long (2011)
10.1158/2326-6066.CIR-14-0150
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Theodore Kouo (2015)
10.1073/pnas.1205575110
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
R. Haq (2013)
Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 2004;23:6031-9
H Sumimoto (2004)
10.1200/JCO.2010.33.9275
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
J. Guo (2011)
10.1016/j.cell.2010.02.027
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
S. Sharma (2010)
10.1016/S1470-2045(15)00083-2
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
A. Ribas (2015)
10.1016/j.coi.2011.12.011
Modulation of GITR for cancer immunotherapy.
D. Schaer (2012)
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
S. Hingorani (2003)
10.1016/J.CCR.2005.04.005
Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.
S. Sebti (2005)
10.1016/j.cell.2009.12.040
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
S. Heidorn (2010)
10.1200/JCO.2012.47.7836
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
F. S. Hodi (2013)
10.1016/S1470-2045(11)70155-3
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
J. F. Jacobs (2012)
10.4161/21624011.2014.955683
The prognostic impact of specific CD4 T-cell responses is critically dependent on the target antigen in melanoma
H. Zelba (2015)
10.1056/NEJMoa1412082
Nivolumab in previously untreated melanoma without BRAF mutation.
C. Robert (2015)
10.1182/blood-2008-12-195792
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.
M. Ahmadzadeh (2009)
10.1158/1078-0432.CCR-12-2064
Agonistic CD40 Antibodies and Cancer Therapy
R. Vonderheide (2013)
10.1056/NEJMoa1103782
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
P. Chapman (2011)
10.1016/j.ccr.2012.10.009
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.
Piro Lito (2012)
10.1158/1078-0432.CCR-11-1987
Sunitinib Therapy for Melanoma Patients with KIT Mutations
D. Minor (2012)
10.1097/CJI.0b013e3181cd8746
Alternatively Activated Macrophage Possess Antitumor Cytotoxicity That Is Induced by IL-4 and Mediated by Arginase-1
J. Ellyard (2010)
10.1158/1078-0432.CCR-13-3122
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
H. Rizos (2014)
10.1128/MCB.5.3.582
Activation of N-ras in a human melanoma cell line.
R. Padua (1985)
10.1097/01.cji.0000190961.34913.e5
CD4 cells can be more efficient at tumor rejection than CD8 cells.
A. Perez-Diez (2007)
10.1038/nature11183
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Ravid Straussman (2012)
10.1001/jama.2011.746
KIT as a therapeutic target in metastatic melanoma.
R. Carvajal (2011)
10.1038/nm.2871
Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion
M. Rangachari (2012)
10.1126/science.1202947
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
O. Qureshi (2011)
Distribution of latexingesting cells, T cells, and B cells in the peripheral blood of patients with malignant melanoma
B Koziner (1975)
Effective tumor immunotherapy: start the engine, release the brakes, step on the gas pedal,...and get ready to face autoimmunity.
I. Tirapu (2002)
10.1158/0008-5472.CAN-06-0384
Epigenetic silencing of the PTEN gene in melanoma.
A. Mirmohammadsadegh (2006)
10.1056/NEJMoa1002011
Inhibition of mutated, activated BRAF in metastatic melanoma.
K. Flaherty (2010)
10.1097/01.CMR.0000232300.22032.86
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing
Esther Edlundh-Rose (2006)
10.1038/nm.2941
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
L. Kwong (2012)
10.1038/ni.2703
Innate and adaptive immune cells in the tumor microenvironment
T. Gajewski (2013)
10.1158/1078-0432.CCR-14-1630
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
R. Carvajal (2015)
10.1097/00002371-200301000-00009
CD4+CD25+ Suppressor Lymphocytes in the Circulation of Patients Immunized Against Melanoma Antigens
L. Javia (2003)
10.1073/pnas.0906481106
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity
Mirna Balsamo (2009)
10.1084/jem.20130579
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
Tyler R. Simpson (2013)
10.1073/pnas.1003345107
Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
J. Matsuzaki (2010)
10.1111/imm.12036
The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells
D. Lindau (2013)
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.
L. Muul (1987)
10.1084/JEM.182.2.459
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
M. Krummel (1995)
10.1084/JEM.176.2.327
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens
E. Baixeras (1992)
10.1158/1078-0432.CCR-11-2479
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
J. Wilmott (2011)
10.1158/1078-0432.CCR-05-1650
Aurora Kinase A Messenger RNA Overexpression Is Correlated with Tumor Progression and Shortened Survival in Head and Neck Squamous Cell Carcinoma
R. Reiter (2006)
10.1016/j.it.2011.07.003
Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy.
R. Houot (2011)
10.1126/science.270.5238.985
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
10.1016/S0140-6736(12)60868-X
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
A. Hauschild (2012)
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
10.1038/34681
MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes
T. Hemesath (1998)
Characterization of the human CD27 ligand, a novel member of the TNF gene family.
R. Hintzen (1994)
10.1016/j.cell.2012.06.024
A Landscape of Driver Mutations in Melanoma
Eran Hodis (2012)
10.1056/NEJMoa1112302
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
J. Sosman (2012)
10.1371/journal.pone.0035309
Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials
Christine M. Lovly (2012)
10.1016/S0140-6736(12)60398-5
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
G. Falchook (2012)
10.1016/S1470-2045(15)70076-8
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
J. Weber (2015)
10.1158/0008-5472.CAN-04-1399
Deregulated Akt3 Activity Promotes Development of Malignant Melanoma
J. Stahl (2004)
10.1158/0008-5472.CAN-14-1339
Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
Lucas Ferrari de Andrade (2014)
10.1186/1479-5876-10-246
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
T. Gajewski (2012)
10.1158/0008-5472.CAN-11-3208
Densely granulated murine NK cells eradicate large solid tumors.
R. B. Liu (2012)
10.1002/path.2798
The GIST paradigm: lessons for other kinase‐driven cancers
C. Antonescu (2011)
10.1038/308069A0
Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?
A. Albino (1984)
10.1101/GAD.1437206
Malignant melanoma: genetics and therapeutics in the genomic era.
L. Chin (2006)
10.1158/1078-0432.CCR-12-2731
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
X. Jiang (2012)
10.1007/s00262-005-0018-5
Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients
J.B.A.G. Haanen (2005)
10.3978/j.issn.2218-6751.2012.12.08
Adaptive resistance to targeted therapies in cancer.
R. Rosell (2013)
10.1182/BLOOD-2005-06-2399
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
M. Ahmadzadeh (2006)
10.1016/S0084-392X(09)79192-0
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
T. Milman (2010)
10.1517/14712598.2015.1069272
Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives
M. Sanlorenzo (2015)
10.1111/j.1365-2133.2007.08057.x
Evaluation of tumour‐infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases
V. Mourmouras (2007)
10.1002/eji.200323382
The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells
C. Workman (2003)
10.1186/ar559
The immunological synapse
Michael Loran Dustin (2002)
10.1016/S1470-2045(14)70072-5
Systemic treatment for BRAF-mutant melanoma: where do we go next?
A. Menzies (2014)
10.1038/ncomms6712
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
J. Müller (2014)
10.1073/pnas.1317577110
Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma
P. Yuan (2013)
10.7554/eLife.11414
Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Vidhu Sharma (2016)
10.1038/SJ.JID.5701185
IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin.
Caroline Hilmi (2008)
10.1038/nature13572
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
L. Boussemart (2014)
10.1038/nature00766
Mutations of the BRAF gene in human cancer
Helen Davies (2002)
10.1182/BLOOD-2005-03-1154
Natural-killer cells and dendritic cells: "l'union fait la force".
T. Walzer (2005)
10.1371/journal.pone.0030852
Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization
Lukas Baitsch (2012)
10.1073/pnas.1418163112
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
D. Perna (2015)
10.1038/ni967
The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses
Woong-Kyung Suh (2003)
10.1038/ncponc1251
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib
A. Quintás-Cardama (2008)
Tumorinfiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
J Matsuzaki (2010)
10.1158/0008-5472.CAN-10-0118
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
A. Boni (2010)
10.1016/j.bbcan.2008.07.003
The Aurora kinase family in cell division and cancer.
G. Vader (2008)
10.1016/J.TIBS.2004.03.006
Advances in protein kinase B signalling: AKTion on multiple fronts.
D. Brazil (2004)
10.1158/0008-5472.CAN-13-1506
VISTA Regulates the Development of Protective Antitumor Immunity.
I. Le Mercier (2014)
10.1158/2159-8290.CD-13-0617
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
E. V. Van Allen (2014)
10.1111/j.1755-148X.2008.00475.x
Dose‐dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
J. Lutzky (2008)
10.1038/nrc3760
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
M. Holderfield (2014)
10.1007/s00262-014-1549-4
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
G. Prendergast (2014)
10.1200/JCO.2007.14.0707
Major response to imatinib mesylate in KIT-mutated melanoma.
F. S. Hodi (2008)
10.1172/JCI65780
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.
E. V. Abel (2013)
10.1038/ni1443
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
A. Sharpe (2007)
10.1158/0008-5472.CAN-03-3066
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.
A. Zippelius (2004)
10.1016/j.canlet.2014.11.033
Ran signaling in melanoma: implications for the development of alternative therapeutic strategies.
E. Caputo (2015)
10.4161/onci.21456
Melanoma immunoediting by NK cells
Mirna Balsamo (2012)
10.1038/sj.onc.1207812
Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference
H. Sumimoto (2004)
10.1158/2159-8290.CD-14-0477
Universes collide: combining immunotherapy with targeted therapy for cancer.
J. Wargo (2014)
10.1016/j.ccr.2010.11.023
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Jessie Villanueva (2010)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1016/1074-7613(95)90125-6
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
10.1038/ni1271
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C. Zhu (2005)
10.1158/0008-5472.CAN-07-2615
Modeling genomic diversity and tumor dependency in malignant melanoma.
W. Lin (2008)
10.1007/BF00241263
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand
B. Huard (2004)
10.1593/TLO.13277
Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors.
Yan Ye (2013)
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 2012;13:e32-42
JF Jacobs (2012)
Vemurafenib enhances Karachaliou et al. Molecular biology of melanoma
B Sapkota (2013)
10.1111/j.1600-065X.2009.00765.x
Immune regulation by 4‐1BB and 4‐1BBL: complexities and challenges
C. Wang (2009)
10.1111/j.1600-065X.2009.00767.x
PD‐1 signaling in primary T cells
J. Riley (2009)
10.1097/CCO.0b013e32834fca92
Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights
R. Dummer (2012)
10.1038/nature11249
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
T. Wilson (2012)
10.1038/nature10662
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
P. Poulikakos (2011)
10.1158/1078-0432.CCR-12-0052
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
A. Menzies (2012)
10.1111/j.1600-065X.2009.00768.x
Fine tuning the immune response through B7‐H3 and B7‐H4
K. H. Yi (2009)
10.1158/0008-5472.CAN-14-0464
Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor.
C. Kugel (2014)
Separate GTP binding and GTPase activating domains of a G alpha Karachaliou et al. Molecular biology of melanoma
DW Markby (1993)
10.1200/JCO.2010.33.2312
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
N. Wagle (2011)
10.1126/scitranslmed.3005753
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma
R. Corcoran (2013)
10.1200/JCO.2014.32.15_SUPPL.9009
A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.
J. Sosman (2014)
10.1038/sj.onc.1203076
Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway
X. Fang (1999)
10.1593/NEO.111102
Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.
Elisabetta Vergani (2011)
10.1158/1078-0432.CCR-14-0759
Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
M. Carlino (2014)
10.1016/j.ccr.2013.05.003
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.
A. Rösch (2013)
10.1016/S0092-8674(00)80405-5
Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery
S. Datta (1997)
10.1093/JNCI/81.24.1893
Model predicting survival in stage I melanoma based on tumor progression.
W. Clark (1989)
GAPs in growth factor signalling. Growth factors 2005;23:143-9
A Bernards (2005)
10.1084/jem.20091918
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
S. Quezada (2010)
10.1158/1078-0432.CCR-08-1144
Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
X. Jiang (2008)
10.1001/JAMAONCOL.2015.0493
Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
N. Thomas (2015)
10.3892/OR.18.5.1115
Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
C. Miracco (2007)
10.1200/JCO.2006.06.2984
Somatic activation of KIT in distinct subtypes of melanoma.
J. A. Curtin (2006)
10.1002/jlb.64.3.275
Tumor‐induced immune dysfunction: the macrophage connection
K. Elgert (1998)
10.1016/j.ccell.2015.03.001
Immune checkpoint blockade: a common denominator approach to cancer therapy.
S. Topalian (2015)
10.1016/J.CCR.2005.09.006
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.
Qing-Bai She (2005)
10.1056/NEJMOA050092
Distinct sets of genetic alterations in melanoma.
J. A. Curtin (2005)
10.1016/j.ccell.2014.10.018
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Robert J. Johnston (2014)
10.1517/14712598.2011.540563
The CD4-like molecule LAG-3, biology and therapeutic applications
S. Sierro (2011)
The prognostic impact Annals of Translational Medicine, Vol 3, No 18 October 2015 Page 19 of 22 © Annals of Translational Medicine
H Zelba (2015)
10.1038/cdd.2012.94
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
Y. Shao (2012)
10.1038/nature14404
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger (2015)
10.1182/blood-2011-12-401067
Human Langerhans cells are immature in melanoma sentinel lymph nodes.
G. Gerlini (2012)
10.1158/2326-6066.CIR-13-0160
Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
M. Callahan (2013)
10.1016/B978-0-12-800267-4.00003-1
Recognition of tumors by the innate immune system and natural killer cells.
A. Marcus (2014)
10.1007/s00262-008-0507-4
Selective accumulation of differentiated FOXP3+ CD4+ T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood
C. Jandus (2008)
10.1074/JBC.M210837200
Identification of a Proline-rich Akt Substrate as a 14-3-3 Binding Partner*
K. Kovacina (2003)
10.1158/1078-0432.CCR-12-0715
Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity
D. Loo (2012)
10.1056/NEJMoa1000584
Mutations in GNA11 in uveal melanoma.
C. D. Van Raamsdonk (2010)
10.1038/sj.bjc.6605714
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
K. Paraiso (2010)
10.1056/NEJMoa1305133
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
10.1167/IOVS.04-0372
HGF protects corneal epithelial cells from apoptosis by the PI-3K/Akt-1/Bad- but not the ERK1/2-mediated signaling pathway.
A. Kakazu (2004)
10.1158/2159-8290.CD-12-0313
Elucidating distinct roles for NF1 in melanomagenesis.
Ophélia Maertens (2013)
10.1038/nrc3973
Evolving synergistic combinations of targeted immunotherapies to combat cancer
I. Melero (2015)
10.1038/nature08902
RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
P. Poulikakos (2010)
10.1038/nature13121
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun (2014)
10.1158/0008-5472.CAN-06-4234
PRAS40 deregulates apoptosis in malignant melanoma.
S. Madhunapantula (2007)
10.1038/nature09626
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
R. Nazarian (2010)
10.1038/nm1093
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
T. Curiel (2004)
10.3389/fonc.2013.00136
Improvement of Cancer Immunotherapy by Combining Molecular Targeted Therapy
Y. Kawakami (2013)
10.1016/j.coi.2014.01.002
Orchestrating immune check-point blockade for cancer immunotherapy in combinations.
J. Pérez-Gracia (2014)
10.1158/0008-5472.CAN-04-4621
Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
S. Al-Batran (2005)
10.1158/0008-5472.CAN-10-2954
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.
K. Paraiso (2011)
10.1080/08977190500130480
GAPs in growth factor signalling
A. Bernards (2005)
10.1158/1078-0432.CCR-14-1015
Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma
H. Zelba (2014)
10.1038/nature13848
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Yu-Hwa Huang (2015)
10.1016/S1470-2045(13)70024-X
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
P. Ascierto (2013)
10.1056/NEJMoa1210093
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
K. Flaherty (2012)
10.1056/NEJMoa1203421
Improved survival with MEK inhibition in BRAF-mutated melanoma.
K. Flaherty (2012)
10.1200/JCO.2007.12.7837
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
E. Korn (2008)
10.3109/08977194.2010.518616
Second AKT: The rise of SGK in cancer signalling
M. A. Bruhn (2010)
10.1056/NEJMoa1406037
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
G. Long (2014)
10.1111/j.1755-148X.2011.00950.x
Role and therapeutic potential of PI3K‐mTOR signaling in de novo resistance to BRAF inhibition
W. Deng (2012)
10.1038/ncomms1727
Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
H. Shi (2012)
10.1038/modpathol.2010.227
Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis
A. Mansfield (2011)
10.1016/J.OHC.2004.07.002
Uveal melanoma: epidemiologic aspects.
A. Singh (2005)
10.1158/1535-7163.MCT-09-0459
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
S. Woodman (2009)
10.1038/nature01646
Role of ERas in promoting tumour-like properties in mouse embryonic stem cells
Kazutoshi Takahashi (2003)
10.1056/NEJMoa1503093
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
C. Robert (2015)
10.1158/1078-0432.CCR-14-2339
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
L. Liu (2015)
10.1038/onc.2013.418
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations
X. Chen (2014)
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
K. Omholt (2003)
10.1073/pnas.0905833106
MEK1 mutations confer resistance to MEK and B-RAF inhibition
C. Emery (2009)
10.1084/JEM.186.1.47
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
W. W. Shuford (1997)
10.1172/JCI27745
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
S. Quezada (2006)
10.1038/nrm2822
The nuts and bolts of AGC protein kinases
Laura R Pearce (2010)
10.1158/2326-6066.CIR-13-0219
Killer Immunoglobulin-like Receptors and Tumor Immunity
D. Benson (2014)
10.1038/onc.2014.249
Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma
A. Rösch (2014)
10.1093/INTIMM/10.10.1563
Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses.
H. Nishimura (1998)
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
10.1158/1078-0432.CCR-10-2276
Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
J. Ellerhorst (2010)
10.1038/nrc3218
From genes to drugs: targeted strategies for melanoma
K. Flaherty (2012)
10.1038/nature05563
Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells
Y. Zheng (2007)
CTLA-4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
SA Quezada (1935)
Function Annals of Translational Medicine, Vol 3, No 18 October 2015 Page 17 of 22 © Annals of Translational Medicine
CH 3rdKugel (2014)
Nivolumab vs. chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
JS Weber (2015)
10.1172/JCI35437
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
M. Cragg (2008)
10.1371/journal.pone.0025806
BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
H. El-Osta (2011)
10.1038/onc.2008.362
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
K. S. Smalley (2009)
10.4049/jimmunol.1100714
Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3
M. Bettini (2011)
10.1158/1078-0432.CCR-13-2797
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad S Atefi (2014)
10.1016/J.CLIM.2007.07.018
Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes.
G. Gerlini (2007)
10.1158/2326-6066.CIR-13-0181
MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells
L. J. Vella (2014)
10.1038/ni987
Tim-3 inhibits T helper type 1–mediated auto- and alloimmune responses and promotes immunological tolerance
A. Sánchez-Fueyo (2003)
10.1158/0008-5472.CAN-07-6787
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
C. Montagut (2008)
10.1182/blood-2009-02-206532
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
F. Romagné (2009)
10.1038/sj.onc.1207780
BRAF alterations are associated with complex mutational profiles in malignant melanoma
M. Daniotti (2004)
10.4049/jimmunol.171.3.1272
Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism1
B. Blazar (2003)
10.1084/jem.20051848
The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
H. Sumimoto (2006)
10.1084/jem.20100619
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
L. Wang (2011)
10.1007/s10637-011-9763-9
Nilotinib in patients with metastatic melanoma harboring KIT gene aberration
J. Cho (2011)
10.1007/s00262-007-0353-9
Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma
F. Hillen (2007)
10.1158/1078-0432.CCR-09-0537
Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers
E. Carpenter (2009)
10.1200/JCO.2007.15.7636
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
A. Hauschild (2009)
10.1056/NEJMoa1414428
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A. Postow (2015)
10.1158/2159-8290.CD-12-0470
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
S. Whittaker (2013)
10.4161/onci.25218
Immunological consequences of selective BRAF inhibitors in malignant melanoma
B. Schilling (2013)
Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.
L. Lauerová (2002)
10.1158/0008-5472.CAN-08-1242
A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans.
F. I. Staquicini (2008)
10.1038/nrc3565
Gene-engineered T cells for cancer therapy
M. Kershaw (2013)
10.1016/j.molcel.2015.05.037
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.
Hee-Bum Kang (2015)
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
P. Guldberg (1997)
10.1172/JCI46102
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.
Lukas Baitsch (2011)
10.1182/blood-2008-06-163048
FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.
M. Ahmadzadeh (2008)
10.1016/j.humpath.2011.02.019
Association between natural killer cells and regression in melanocytic lesions.
Kristopher McKay (2011)
10.1126/SCIENCE.8266082
Separate GTP binding and GTPase activating domains of a G alpha subunit.
D. W. Markby (1993)
10.4049/jimmunol.1490019
IL-2: The First Effective Immunotherapy for Human Cancer
S. Rosenberg (2014)
10.1038/sj.onc.1207785
B-RAF is a therapeutic target in melanoma
M. Karasarides (2004)
10.1038/ni.2762
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
T. Okazaki (2013)
10.1158/1078-0432.CCR-12-1630
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
D. Frederick (2013)
10.1158/1078-0432.CCR-07-5268
Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer
Y. Nadler (2008)
10.1182/blood-2007-11-120998
Tumor-specific Th17-polarized cells eradicate large established melanoma.
P. Muranski (2008)
10.1126/scitranslmed.aaa4691
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
S. Hu-Lieskovan (2015)
10.4161/onci.22890
Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells
B. Sapkota (2013)
10.1007/s00262-011-1071-x
Prognostic impact of B-cell density in cutaneous melanoma
A. Ladányi (2011)
10.1101/gad.187252.112
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
L. C. Vredeveld (2012)
Melanoma: oncogenic drivers and the immune system
N Karachaliou (2015)
10.1093/INTIMM/8.5.725
LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice.
T. Miyazaki (1996)
10.1093/JNCI/55.6.1295
Distribution of latex-ingesting cells, T cells, and B cells in the peripheral blood of patients with malignant melanoma.
B. Koziner (1975)
10.1002/eji.200636428
Anti‐OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses
C. Ruby (2007)
10.1158/2159-8290.CD-12-0386
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
M. R. Girotti (2013)
10.1200/JCO.2012.42.1529
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
K. Flaherty (2013)
10.1002/14651858.CD008955.pub2
Interferon alpha for the adjuvant treatment of cutaneous melanoma.
S. Mocellin (2013)
10.1038/nature08833
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
G. Hatzivassiliou (2010)
10.1042/BJ20121212
The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.
M. J. Sale (2013)
10.4049/jimmunol.173.2.1444
Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells1
M. Viguier (2004)
10.1038/jid.2009.182
The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population.
E. Hacker (2010)
The BRAFKarachaliou et al. Molecular biology of melanoma © Annals of Translational Medicine
H Sumimoto (2006)
Systemic treatment for BRAFmutant melanoma: where do we go next? Lancet Oncol 2014;15:e371-81
AM Menzies (2014)
10.1128/MCB.12.10.4687
Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells.
G. Kalinec (1992)
10.1200/JCO.2011.37.9644
Major response to everolimus in melanoma with acquired imatinib resistance.
L. Si (2012)
10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma
C. Clemente (1996)
10.1158/0008-5472.CAN-09-4471
Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.
Y. Shao (2010)
10.1126/SCIENCE.286.5443.1358
Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms.
A. Bonni (1999)
10.1016/S0002-9440(10)64627-5
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
X. Zhou (2000)
10.1371/journal.pone.0101286
Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics
D. Frederick (2014)



This paper is referenced by
10.1038/s41598-018-37883-y
A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy
Emily J Lelliott (2019)
10.1002/jcb.28281
1α, 25‐Dihydroxyvitamin D3 alters ectonucleotidase expression and activity in human cutaneous melanoma cells
M. Bagatini (2019)
10.1158/1535-7163.MCT-16-0881
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma
J. Ang (2017)
10.1038/s41598-019-53636-x
A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants
Ivana Tichá (2019)
10.1136/jclinpath-2016-204025
The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing
M. Yeo (2016)
Investigating the Roles of Fucosylation and Calcium Signaling in Melanoma Invasion
Tyler Keeley (2018)
10.4103/0971-5916.180197
Immune based therapy for melanoma
Robert Ancuceanu (2016)
10.1136/bcr-2016-215012
Limbic encephalitis following immunotherapy against metastatic malignant melanoma
S. Salam (2016)
10.3390/cancers12010021
Chaperoning STAT3/5 by Heat Shock Proteins: Interest of Their Targeting in Cancer Therapy
Gaëtan Jego (2019)
10.1111/pcmr.12599
Immunoregulatory protein B7‐H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells
K. Flem-Karlsen (2017)
10.1172/JCI86953
NLRC4 suppresses melanoma tumor progression independently of inflammasome activation.
Ann M. Janowski (2016)
10.1177/1010428317707423
Downregulation of β-catenin blocks fibrosis via Wnt2 signaling in human keloid fibroblasts
Yumei Cai (2017)
10.3389/fonc.2019.01148
Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells
M. Tucci (2019)
10.1016/j.drudis.2016.05.008
Immune-competent human skin disease models.
L. Bergers (2016)
10.1186/s12859-016-1141-3
Profiling networks of distinct immune-cells in tumors
Trevor Clancy (2016)
10.1158/2159-8290.CD-20-0844
Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy.
S. Fendt (2020)
10.3892/or.2017.5672
Coptidis Rhizoma induces intrinsic apoptosis through BAX and BAK activation in human melanoma.
Xiaoou Xu (2017)
10.5772/64733
The Emerging Epigenetic Landscape in Melanoma
R. A. Rollins (2016)
Semantic Scholar Logo Some data provided by SemanticScholar